Why the study?
Does INO-1001 inhibit PARP activation in circulating leukocytes following myocardial ischemia-reperfusion in rats?
Does INO-1001 inhibit PARP activation in circulating leukocytes following myocardial ischemia-reperfusion in rats?
Local myocardial ischemia-reperfusion injury activates PARP in circulating leukocytes, a process that can be pharmacologically inhibited and may mediate systemic inflammatory responses.
Supports targeting PARP to reduce systemic effects of myocardial ischemia-reperfusion; leaves open clinical translation of INO-1001.
Myocardial ischemia-reperfusion can lead to increased oxidative stress both locally and in circulating leukocytes. Oxidant-mediated DNA single strand breaks are known to activate the nuclear enzyme poly(ADP-ribose) polymerase (PARP) in various forms of shock, inflammation, and ischemia-reperfusion injury. The aim of the current study was to investigate whether a local insult such as myocardial ischemia-reperfusion is sufficient to lead to activation of PARP in circulating leukocytes. In anesthetized rats myocardial ischemia-reperfusion was induced by transient ligation of the left anterior descending coronary artery. There was a marked increase in poly(ADP-ribosyl)ation of proteins in homogenates of leukocytes isolated from rats at the end of the reperfusion period. Poly(ADP-ribosyl)ation was inhibited by administration of the pharmacologic PARP inhibitor INO-1001 (30 mg/kg) to the rats. We conclude that local insults, such as myocardial reperfusion injury, are sufficient to activate PARP in circulating leukocytes. PARP activation in circulating cells may mediate certain systemic effects of local ischemia-reperfusion injury such as inflammatory mediator production and remote organ injury.
No takes yet. Share an insight, caveat, or question.
Murthy et al. (2004) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: